Bayer lapse exposes pharma's vulnerability.
Hodgson
J
J
D000924:Anticholesteremic Agents / Q000009:adverse effects*; D004345:Drug Industry; D006801:Humans; D011358:Product Surveillance, Postmarketing; D011725:Pyridines / Q000009:adverse effects* / Q000191:economics; D012106:Research; D012207:Rhabdomyoma / Q000139:chemically induced*
D000924:Anticholesteremic Agents; D011725:Pyridines; C086276:cerivastatin